|
End-of-day quote
New Zealand S.E.
2026-08-17
|
5-day change | 1st Jan Change | ||
| 4.300 NZD | -2.27% |
|
-6.52% | +27.22% |
| 07-31 | AFT Pharmaceuticals Limited - Shareholder/Analyst Call | |
| 07-31 | New Zealand Shares Fall; AFT Pharmaceuticals Chair to Retire | MT |
Company Valuation: AFT Pharmaceuticals Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 378 | 362.8 | 328.2 | 282.1 | 352.4 | 451 | - | - |
| Change | - | -4% | -9.54% | -14.06% | 24.91% | 27.99% | - | - |
| Enterprise Value (EV) 1 | 407.3 | 392.7 | 344.4 | 296.6 | 391 | 480.8 | 475.6 | 471.1 |
| Change | - | -3.57% | -12.3% | -13.89% | 31.82% | 22.98% | -1.09% | -0.94% |
| P/E | 19x | 34.6x | 20.9x | 24.5x | 24x | 22.9x | 18.2x | 17x |
| PBR | 6.66x | 4.95x | 3.74x | 2.89x | 3.2x | 4.93x | 4.11x | 3.39x |
| PEG | - | -0.7x | 0.4x | -0.9x | 0.9x | 0.7x | 0.7x | 2.41x |
| Capitalization / Revenue | 2.9x | 2.32x | 1.68x | 1.36x | 1.38x | 1.48x | 1.31x | 1.15x |
| EV / Revenue | 3.13x | 2.51x | 1.76x | 1.43x | 1.53x | 1.58x | 1.38x | 1.2x |
| EV / EBITDA | 19x | 18.4x | 13.1x | 14.2x | 13.6x | 13.9x | 11.5x | 9.44x |
| EV / EBIT | 20x | 20x | 14.2x | 16.8x | 16x | 15.7x | 12.8x | 10.4x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | 0.016 | 0.018 | 0.025 | 0.0328 | 0.0416 | 0.0652 |
| Rate of return | - | - | 0.51% | 0.67% | 0.74% | 0.76% | 0.97% | 1.52% |
| EPS 2 | 0.19 | 0.1 | 0.15 | 0.11 | 0.14 | 0.1878 | 0.2366 | 0.2533 |
| Distribution rate | - | - | 10.7% | 16.4% | 17.9% | 17.4% | 17.6% | 25.7% |
| Net sales 1 | 130.3 | 156.6 | 195.4 | 208 | 254.7 | 303.8 | 345.2 | 392.5 |
| EBITDA 1 | 21.43 | 21.39 | 26.25 | 20.88 | 28.8 | 34.63 | 41.41 | 49.9 |
| EBIT 1 | 20.39 | 19.67 | 24.24 | 17.65 | 24.44 | 30.64 | 37.05 | 45.17 |
| Net income 1 | 19.85 | 10.65 | 15.61 | 11.96 | 14.73 | 19.7 | 24.81 | 26.56 |
| Net Debt 1 | 29.3 | 29.9 | 16.2 | 14.5 | 38.6 | 29.84 | 24.6 | 20.14 |
| Reference price 2 | 3.610 | 3.460 | 3.130 | 2.690 | 3.360 | 4.300 | 4.300 | 4.300 |
| Nbr of stocks (in thousands) | 104,697 | 104,866 | 104,866 | 104,866 | 104,866 | 104,875 | - | - |
| Announcement Date | 5/22/22 | 5/22/23 | 5/22/24 | 5/21/25 | 5/20/26 | - | - | - |
1NZD in Million2NZD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 22.89x | 1.58x | 13.89x | 0.76% | 266M | |
| 33.85x | 12.21x | 24.91x | 0.58% | 1,055B | |
| 29.18x | - | - | 2.05% | 632B | |
| 31.95x | 7.44x | 15.46x | 2.74% | 442B | |
| 19.84x | 4.71x | 11.68x | 2.81% | 351B | |
| 21.63x | 5.59x | 13.89x | 2.87% | 290B | |
| 20.07x | 4.15x | 11.78x | 2.12% | 243B | |
| 26.53x | 6.9x | 12.24x | 2.4% | 227B | |
| 13.3x | 4.74x | 9.93x | 3.86% | 200B | |
| -42.45x | 6.16x | 24.05x | 2.37% | 172B | |
| Average | 17.68x | 5.94x | 15.32x | 2.26% | 361.28B | |
| Weighted average by Cap. | 24.29x | 8.06x | 17.79x | 1.99% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AFT Stock
- Valuation AFT Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
